Advertisement

Topics

BMS-Pfizer Alliance to Unveil Real-World Data Analyses – Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation

17:04 EST 10 Nov 2017 | Biotech 365

Analyses from RWD program, ACROPOLIS, use two large U.S. databases to provide insights on Eliquis® (apixaban), warfarin, and other direct oral anticoagulants in patients with NVAF at 2017 American Heart Association (AHA) Scientific Sessions PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–Bristol-Myers … Continue reading

Cet article BMS-Pfizer Alliance to Unveil Real-World Data Analyses – Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation est apparu en premier sur Biotech 365.

Original Article: BMS-Pfizer Alliance to Unveil Real-World Data Analyses – Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation

NEXT ARTICLE

More From BioPortfolio on "BMS-Pfizer Alliance to Unveil Real-World Data Analyses – Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...